Evidence map›Paper›PMID 41575354›Full record

ArticleJournal of medicinal chemistry2026

Tumor-Targeted Delivery of an EGFR Inhibitor Prodrug via Site-Specific Albumin Conjugation.

Anja Federa, Rastislav Pitek, Orsolya Dömötör, Éva A Enyedy, Alessio Terenzi, Monika Caban, Alessia Stefanelli, Luisa D'Anna, Faye White, Petra Heffeter and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anja FederaInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Str. 42, A-1090 Vienna, Austria.
Rastislav PitekCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Orsolya DömötörDepartment of Molecular and Analytical Chemistry, University of Szeged, Dóm tér 7-8, H-6720 Szeged, Hungary.
Éva A EnyedyDepartment of Molecular and Analytical Chemistry, University of Szeged, Dóm tér 7-8, H-6720 Szeged, Hungary.ORCID 0000-0002-8058-8128
Alessio TerenziDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Viale delle Scienze, Edificio 17, 90128 Palermo, Italy.ORCID 0000-0001-9751-1373
Monika CabanCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Alessia StefanelliCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Luisa D'AnnaDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Viale delle Scienze, Edificio 17, 90128 Palermo, Italy.ORCID 0000-0002-7046-5140
Faye WhiteCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.ORCID 0009-0008-9779-5466
Petra HeffeterCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.ORCID 0000-0001-6401-8646
Christian R KowolInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Str. 42, A-1090 Vienna, Austria.ORCID 0000-0002-8311-1632

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Albumin is a promising vehicle for anticancer drug delivery due to its high plasma concentration, long half-life and known tumor accumulation. Drugs can be covalently conjugated to albumin via the free thiol at Cys

Indexed as

AlbuminsAntineoplastic AgentsDrug Delivery SystemsProdrugsProtein Kinase InhibitorsAcrylamidesAniline CompoundsAnimalsCarcinoma, Non-Small-Cell LungCathepsin BCell Line, TumorErbB ReceptorsFemaleHumansIndolesLung NeoplasmsAcrylamidesAlbuminsAniline CompoundsAntineoplastic AgentsCathepsin BEGFR protein, humanErbB ReceptorsIndolesMaleimidesosimertinibProdrugsProtein Kinase InhibitorsPyrimidines

Identifiers

PMID41575354
PMCPMC12910647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.